<DOC>
	<DOCNO>NCT00454480</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , gemtuzumab ozogamicin , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Tipifarnib may stop growth cancer cell block enzymes need cell growth . Giving combination chemotherapy together gemtuzumab ozogamicin tipifarnib may kill cancer cell . PURPOSE : This randomized phase II/III trial study different combination chemotherapy regimens compare well work give without gemtuzumab ozogamicin tipifarnib treat patient acute myeloid leukemia high-risk myelodysplastic syndrome .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Gemtuzumab Ozogamicin Tipifarnib Treating Patients With Acute Myeloid Leukemia High-Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary ( patient consider fit intensive treatment ) - Compare efficacy toxicity daunorubicin hydrochloride cytarabine ( DA ) v daunorubicin hydrochloride clofarabine ( DClo ) induction therapy old patient acute myeloid leukemia high-risk myelodysplastic syndrome . - Assess value gemtuzumab ozogamicin give combination DA DClo course 1 induction therapy . - Compare total two vs three course treatment patient achieve least partial remission ( &lt; 15 % blast ) course 1 induction therapy . - Compare use demethylation maintenance therapy comprise azacitidine vs maintenance therapy patient . - Assess value reduced-intensity allogeneic stem cell transplantation consolidation patient match donor . Primary ( patient consider unfit intensive treatment ) - Compare efficacy toxicity low-dose cytarabine v without gemtuzumab ozogamicin patient . - Compare efficacy toxicity low-dose cytarabine v without arsenic trioxide patient . - Compare efficacy toxicity low-dose cytarabine v low-dose clofarabine patient . Secondary - Evaluate relevance presence cytogenetic abnormality bone marrow patient morphological remission . - Correlate molecular detection FLT3 RAS mutation , genetic signature , resistance protein status response treatment . - Evaluate method minimal residual disease monitoring . - Correlate gene methylation status treatment maintenance azacitidine . OUTLINE : This randomize , control , factorial design , prospective , multicenter study . Patients stratify accord age ( &lt; 60 year vs 60-64 year v 65-69 year v 70-74 year vs ≥ 75 year ) , performance status , WBC count ( 0-9.9,000/mm³ v 10-49.9,000/mm³ vs 50-99.9,000/mm³ v ≥ 100,000/mm³ ) , type disease ( de novo acute myeloid leukemia [ AML ] v secondary AML v high-risk myelodysplastic syndrome ) . Patients receive treatment accord disease status ( fit intensive treatment v unfit intensive treatment ) . - Intensive treatment ( patient consider fit intensive treatment ) : - Induction therapy : Patients randomize 1 4 treatment arm . - Arm I : For course 1 , patient receive daunorubicin hydrochloride ( DH ) IV 1 hour day 1 , 3 , 5 cytarabine IV twice daily day 1-10 . For course 2 , patient receive DH course 1 cytarabine IV twice daily day 1-8 . Courses 4 week duration . - Arm II : Patients receive DH IV 1 hour day 1 , 3 , 5 clofarabine IV 1 hour day 1-5 . Treatment repeat every 4 week 2 course . - Arm III : For course 1 , patient receive DH IV 1 hour day 1 , 3 , 5 , cytarabine IV twice daily day 1-10 , gemtuzumab ozogamicin ( GO ) IV 2 hour day 1 . For course 2 , patient receive DH course 1 cytarabine IV twice daily day 1-8 . Courses 4 week duration . - Arm IV : For course 1 , patient receive DH clofarabine arm II GO arm III . For course 2 , patient receive DH clofarabine arm II . Courses 4 week duration . Patients fail achieve partial remission ( PR ) complete remission ( CR ) course 1 achieve CR course 2 receive third course chemotherapy comprise DH IV 1 hour day 1 3 cytarabine IV twice daily day 1-5 . Patients proceed randomization maintenance therapy . Patients achieve PR CR course 1 CR course 2 randomized receive receive third course chemotherapy ( ) . Patients proceed randomization maintenance therapy . Patients HLA-matched donor may proceed nonintensive allogeneic stem cell transplantation ( ASCT ) . - Nonintensive ASCT : Patients receive nonintensive allograft comprise 1 2 mini-allograft protocol . - Protocol 1 : Patients receive fludarabine day -9 -5 , busulfan day -3 -2 , alemtuzumab day -5 -1 . Patients undergo ASCT day 0 . - Protocol 2 : Patients receive fludarabine day -7 -3 , melphalan day -2 , alemtuzumab day -8 -4 . Patients undergo ASCT day 0 . - Maintenance Therapy : Patients randomize 1 2 treatment arm . - Arm I : Patients receive azacitidine subcutaneously ( SC ) daily day 1-5 . Treatment repeat every 6 week 9 course absence disease progression unacceptable toxicity . - Arm II : Patients receive maintenance therapy . - Nonintensive treatment ( patient consider unfit intensive treatment ) : Patients randomize 1 4 treatment arm . - Arm I : Patients receive low-dose cytarabine ( LDC ) SC twice daily day 1-10 . - Arm II : Patients receive LDC arm I GO IV 2 hour day 1 . - Arm III : Patients receive low-dose clofarabine IV 1 hour daily day 1-5 . - Arm IV : Patients receive LDC arm I arsenic trioxide IV 1-2 hour day 1-5 , 9 , 11 . Treatment arm repeat every 4-6 week 4 course absence disease progression unacceptable toxicity . Bone marrow collect diagnosis examine characterization FLT3 RAS mutation immunophenotyping , gene expression DNA microarray , cytogenetic analysis . Blood sample collect baseline 18 , 36 , 54 week treatment assessment gene methylation status . After completion study therapy , patient follow 6 12 month annually thereafter . PROJECTED ACCRUAL : A total 2,000 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Acute myeloid leukemia ( AML ) meeting follow criterion : De novo secondary AML No acute promyelocytic leukemia Highrisk myelodysplastic syndrome ( &gt; 10 % marrow blast ; refractory anemia excess blasts2 ) No blast transformation chronic myeloid leukemia Patients ≤ 60 year age may eligible provide consider unfit clinical trial MRCAMLI5 PATIENT CHARACTERISTICS : Not pregnant nursing AST ALT ≤ 2 time upper limit normal ( ULN ) ( patient receive gemtuzumab ozogamicin ) Bilirubin ≤ 2 time ULN ( patient receive gemtuzumab ozogamicin ) Creatinine normal ( patient receive clofarabine ) No concurrent active malignancy except basal cell carcinoma PRIOR CONCURRENT THERAPY : No prior cytotoxic chemotherapy AML Hydroxyurea similar lowdose therapy control WBC count prior initiation intensive therapy allow No concurrent enzyme anticonvulsant , include phenytoin , phenobarbital , primidone , carbamazepine , oxcarbazepine ( patient receive tipifarnib )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>